<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier		N/A; This is a
name, catalogue number and RRID, if available.		retrospective
		study

Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain.		N/A; This is a
Provide accession number in repository OR		retrospective
supplier name, catalog number, clone number,		study
OR RRID		
Primary cultures: Provide species, strain, sex of		N/A; This is a
origin, genetic modification status.		retrospective

Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age,		N/A; This is a
genetic modification status. Provide accession		retrospective
number in repository OR supplier name, catalog		study
number, clone number, OR RRID		
Animal observed in or captured from the		N/A; This is a
field: Provide species, sex and age where		retrospective
possible		study
Model organisms: Provide Accession number		N/A; This is a
in repository (where relevant) OR RRID		retrospective

Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		N/A; This is a retrospective study
Microbes: provide species and strain, unique accession number if available, and source		N/A; This is a retrospective

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes, the Ethics Committee of Shanghai Tenth People's Hospital, School of Medicine, Tongji University approved this study (SHSY-IEC-KY- 4.0/18-68/01); Clinical materialssection of Patients and methods and paragraph 6	
Provide statement confirming informed consent obtained from study participants.	Yes, it was provided in the methods section; Clinical materials methods section of Patients and methods and paragraph 6.	
Report on age and sex for all study participants.	Yes, it was provided in the results section; General information of patients section of Results and paragraph 10	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.		N/A; This is a retrospective study
Laboratory protocol Provide DOI or other citation details if detailed step-by-step protocols are available.	Yes (indicate where provided: section/paragraph)	n/a N/A; This is a retrospective study
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.	(, р, р	,.
Sample size determination	Yes. it was provided in the methods section; Clinical materials methods section of Patients and methods and paragraph 4,5.	
Randomisation		N/A; This is a retrospective study
Blinding		N/A; This is a retrospective study
Inclusion/exclusion criteria	Yes. it was provided in the methods section.; Clinical materials methods section of Patients and methods and paragraph 4,5.	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was		N/A; This is a
replicated in laboratory		retrospective
Define whether data describe technical or biological replicates		N/A; This is a retrospective
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes. it was provided in the methods section; Clinical materialssection of Patients and methods and paragraph 6	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number		N/A; This is a retrospective study
for approval. Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		N/A; This is a retrospective study
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		N/A; This is a retrospective study

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is	Yes. it was provided in the methods	
excluded, and whether the criteria for exclusion were	section.; Clinical materials methods section	
determined and specified in advance.	of Patients and methods and paragraph	

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of	Yes. it was provided in the methods	
tests.	section.	

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available,	Yes. it was provided in the footnote.;	
including protocols for access or restriction on	Statistical method section of Patients and	
access.	methods and paragraph 9.	
If data are publicly available, provide accession		N/A; This is a
number in repository or DOI or URL.		retrospective
If publicly available data are reused, provide		N/A; This is a
accession number in repository or DOI or URL, where		retrospective
possible.		study

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.		N/A; This is a
If code is publicly available, provide accession		N/A; This is a
number in repository, or DOI or URL.		retrospective

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/apm-20-985